Alimera Sciences Sues ANI Pharmaceuticals for Delays in Merger Close
Alimera Sciences (ALIM) said Tuesday it filed a lawsuit in the Delaware Court of Chancery to force ANI Pharmaceuticals (ANIP) to complete their merger.
"Alimera has fulfilled all its requirements to close the merger agreement, yet ANI has failed to adhere to its obligation to close on time," the company added.
ANI said Tuesday it is working in good faith to complete the transaction and plans to promptly resolve any delays resulting from discussions about the closing conditions.
ANI agreed to acquire Alimera in June in a deal valued at around $381 million.
Alimera and ANI shares were down 6.7% and 5.3% in recent trading, respectively.
Price: 5.16, Change: -0.40, Percent Change: -7.12
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.